Dr. Peter Q. Jiang, M.D., PH.D
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 596
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301075266 · GA license 59981
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Piedmont Columbus Regional Midtown Columbus, GA
- St Francis Hospital- Emory Healthcare Columbus, GA
- Piedmont Columbus Regional Northside Columbus, GA
Medical groups
- The Medical Center, Inc. (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 596
- Services billed
- 2,270
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,239 | 438 |
| Established patient office or other outpatient visit, 40-54 minutes | 264 | 118 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 230 | 91 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 192 | 82 |
| Established patient office or other outpatient visit, 20-29 minutes | 136 | 124 |
| New patient office or other outpatient visit, 45-59 minutes | 84 | 84 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 63 | 57 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 31 | 25 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Columbus, GA | 211 |
| Ondansetron Hcl Other prescribers in Columbus, GA | 132 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Columbus, GA | 131 |
| Gabapentin Other prescribers in Columbus, GA | 130 |
| Prednisone Other prescribers in Columbus, GA | 123 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Columbus, GA | 101 |
| Dexamethasone Other prescribers in Columbus, GA | 90 |
| Prochlorperazine Maleate Other prescribers in Columbus, GA | 89 |
| Hydroxyurea Other prescribers in Columbus, GA | 82 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Columbus, GA | 81 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 27 payments worth $9,783 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $4,369 |
|---|---|
| Astellas Pharma US Inc | $2,479 |
| Incyte Corporation | $860 |
| Geron Corporation | $780 |
| Daiichi Sankyo Inc. | $672 |
| Janssen Scientific Affairs, LLC | $150 |
| Beone Medicines USA, Inc. | $134 |
| Janssen Biotech, Inc. | $99.99 |
| Consulting Fee | $8,565 |
|---|---|
| Food and Beverage | $602 |
| Travel and Lodging | $413 |
| Education | $203 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Apr 14, 2025 | Consulting Fee Vyloy · Oncology | $2,000 |
| AstraZeneca Pharmaceuticals LP Oct 22, 2025 | Consulting Fee | $1,650 |
| AstraZeneca Pharmaceuticals LP May 16, 2025 | Consulting Fee | $1,375 |
| AstraZeneca Pharmaceuticals LP May 28, 2025 | Consulting Fee IMFINZI · Oncology | $1,100 |
| Incyte Corporation Mar 15, 2025 | Consulting Fee | $860 |
| Geron Corporation Apr 30, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $780 |
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Astellas Pharma US Inc Apr 4, 2025 | Travel and Lodging Vyloy · Oncology · travel to Phoenix, AZ | $267 |
| Janssen Scientific Affairs, LLC Jul 11, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| Astellas Pharma US Inc Apr 4, 2025 | Travel and Lodging Vyloy · Oncology · travel to Phoenix, AZ | $123 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Oct 22, 2025 | Consulting Fee | $1,650 |
| Gilead Sciences, Inc. Oct 13, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4203836;GTF;10894711 | $77.99 |
| Janssen Biotech, Inc. Oct 6, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.99 |
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Janssen Scientific Affairs, LLC Jul 11, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| Genmab U.S., Inc. Jun 10, 2025 | Education Epkinly · Oncology · in-kind | $25.00 |
| AstraZeneca Pharmaceuticals LP May 28, 2025 | Consulting Fee IMFINZI · Oncology | $1,100 |
| AstraZeneca Pharmaceuticals LP May 16, 2025 | Consulting Fee | $1,375 |
| Geron Corporation Apr 30, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $780 |
| Astellas Pharma US Inc Apr 14, 2025 | Consulting Fee Vyloy · Oncology | $2,000 |
| Astellas Pharma US Inc Apr 4, 2025 | Travel and Lodging Vyloy · Oncology · travel to Phoenix, AZ | $267 |
| Astellas Pharma US Inc Apr 4, 2025 | Travel and Lodging Vyloy · Oncology · travel to Phoenix, AZ | $123 |
| Astellas Pharma US Inc Apr 4, 2025 | Travel and Lodging Vyloy · Oncology · travel to Phoenix, AZ | $23.50 |
| Incyte Corporation Mar 15, 2025 | Consulting Fee | $860 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,600 in research payments for these studies, mostly to the institutions running them.
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.